TY - JOUR
TI - Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease
AU - Roggenbuck, D.
AU - Vermeire, S.
AU - Hoffman, I.
AU - Reinhold, D.
AU - Schierack, P.
AU - Goihl, A.
AU - Von Arnim, U.
AU - De Hertogh, G.
AU - Polymeros, D.
AU - Bogdanos, D.P.
AU - Bossuyt, X.
JO - Clinical Chemistry and Laboratory Medicine (CCLM)
PY - 2015
VL - 53
TODO - 9
SP - 1349-1357
PB - Walter de Gruyter GmbH
SN - null
TODO - 10.1515/cclm-2014-0238
TODO - autoantibody;  bispecific antibody;  gliadin antibody;  glutamate decarboxylase;  glycoprotein 2 antibody;  immunoglobulin A antibody;  immunoglobulin G antibody;  protein antibody;  protein glutamine gamma glutamyltransferase antibody;  unclassified drug;  autoantibody;  glycosylphosphatidylinositol anchored protein;  GP2 protein, human;  immunoglobulin A;  immunoglobulin G, adolescent;  adult;  antibody blood level;  Article;  blood donor;  celiac disease;  child;  comparative study;  Crohn disease;  enzyme linked immunosorbent assay;  female;  human;  immunological tolerance;  major clinical study;  male;  priority journal;  blood;  case control study;  celiac disease;  cohort analysis;  Crohn disease;  follow up;  immunology;  insulin dependent diabetes mellitus;  time factor;  young adult, Adolescent;  Adult;  Autoantibodies;  Case-Control Studies;  Celiac Disease;  Child;  Cohort Studies;  Crohn Disease;  Diabetes Mellitus, Type 1;  Female;  Follow-Up Studies;  GPI-Linked Proteins;  Humans;  Immunoglobulin A;  Immunoglobulin G;  Male;  Time Factors;  Young Adult
TODO - Background: Autoantibodies to exocrine-pancreatic glycoprotein 2 (anti-GP2) are Crohn's disease (CD) markers. However, CD-specific antibodies have also been found in celiac-disease (CeD) patients, in which type 1 diabetes-specific autoantibodies against endocrine pancreatic targets can be present. We investigated whether anti-GP2 are also present in CeD, a disease like CD which is also characterised by intestinal mucosal inflammation with barrier impairment. Methods: Antibodies against GP2, tissue transglutaminase (tTG), deamidated gliadin (dGD), glutamic decarboxylase (GAD), and islet antigen-2 (IA2) were tested in sera from 73 CD patients, 90 blood donors (BD), and 79 (58 de novo) CeD patients (2 consecutive sera were available from 40 patients). Results: IgA and/or IgG anti-GP2 were found in 15/79 (19.0%) CeD patients on at least one occasion, in 25/73 (34.2%) CD patients, and in 4/90 (4.4%) BD (CeD vs. CD, p=0.042; BD vs. CeD and CD, p<0.001, respectively). Amongst the 58 de novo CeD patients, anti-GP2 IgA and/or IgG were present in 11 (19.0%). Anti-GP2 IgA was significantly less prevalent in CeD compared with CD (p=0.004). Anti-GP2 IgA and IgG in CD patients demonstrated a significantly higher median level compared to patients with CeD (p<0.001, p=0.008, respectively). IgA anti-GP2 levels correlated significantly with IgA anti-tTG and anti-dGD levels in CeD Spearman's coefficient of rank correlation (ρ)=0.42, confidence interval (CI): 0.26-0.56, p<0.001; ρ=0.54, CI 0.39-0.65, p<0.001, respectively. Conclusions: The presence of anti-GP2 in CeD patients supports the notion that loss of tolerance to GP2 can probably be a manifestation of an autoinflammatory process in this intestinal disorder. © 2015 by De Gruyter.
ER -